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Metformin for the Treatment
of the Polycystic Ovary Syndrome
John E. Nestler, M.D.
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion
of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies,
the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines,
if they exist, are presented. The article ends with the author’s clinical recommendations.

A 23-year-old woman with known polycystic ovary syndrome visits her family physician. She has taken oral contraceptive pills in the past but did not tolerate them and is
not currently receiving any treatment. She has three or four menstrual periods per
year and is not interested in becoming pregnant now, but she will be getting married
in a year. She has heard that the polycystic ovary syndrome is associated with diabetes
and is concerned because both her mother and father have type 2 diabetes. Her bodymass index (the weight in kilograms divided by the square of the height in meters) is
32, her waist circumference is 38 in. (96.5 cm), her serum total testosterone level is
elevated at 0.9 ng per milliliter (90 ng per deciliter, or 2.9 nmol per liter), her plasma
high-density lipoprotein cholesterol level is 35 mg per deciliter (0.9 mmol per liter),
and her triglyceride level is 190 mg per deciliter (2.1 mmol per liter). Her serum
glucose level 2 hours after the ingestion of 75 g of dextrose is 138 mg per deciliter
(7.7 mmol per liter). The physician wonders whether treatment with metformin
would be beneficial and refers the patient to an endocrinologist.

The Cl inic a l Probl e m
The polycystic ovary syndrome is a clinical diagnosis characterized by the presence
of two or more of the following features: chronic oligo-ovulation or anovulation,
androgen excess, and polycystic ovaries.1 It affects 5 to 10% of women of childbearing age2,3 and is the most common cause of anovulatory infertility in developed
countries. Common clinical manifestations include menstrual irregularities and
signs of androgen excess such as hirsutism, acne, and alopecia.
The polycystic ovary syndrome is associated with important metabolic derangements. The prevalence of type 2 diabetes in the United States is 10 times as high
among young women with the polycystic ovary syndrome as among normal
women,4,5 and impaired glucose tolerance or overt type 2 diabetes develops by the
age of 30 years in 30 to 50% of obese women with the polycystic ovary syndrome.4‑6
The prevalence of the metabolic syndrome is two to three times as high among
women with the polycystic ovary syndrome as among normal women matched for
age and body-mass index, and 20% of women with the polycystic ovary syndrome
who are younger than 20 years of age have the metabolic syndrome.7 Although
outcome data specifically for women with the polycystic ovary syndrome are lacking, the risk of fatal myocardial infarction is twice as high among women with
severe oligomenorrhea, most of whom would be expected to have the polycystic
ovary syndrome, as among women with eumenorrhea.8
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Pathoph ysiol o gy a nd Effec t
of Ther a py
The pathophysiological characteristics of the polycystic ovary syndrome are not fully understood
but are known to involve complex interactions between the actions of gonadotropins, the ovaries,
androgens, and insulin (Fig. 1). An important element of this syndrome is insulin resistance. The
majority of women with the polycystic ovary syndrome, regardless of weight, have a form of insulin resistance that is intrinsic to the syndrome and
is poorly understood.9-11 Obese women with the
polycystic ovary syndrome have an added burden
of insulin resistance related to their adiposity.11
The insulin resistance that is characteristic of
the polycystic ovary syndrome appears to be responsible for the association of the disorder with
type 2 diabetes.12 Insulin resistance may also
underlie the association of the polycystic ovary
syndrome with recognized cardiovascular risk fac
tors such as dyslipidemia and hypertension,13 as
well as with anatomical14-17 and functional16,18,19
cardiovascular derangements.
Insulin resistance and compensatory hyperinsulinemia also play an important role in other
aspects of the polycystic ovary syndrome, including androgen excess and anovulation (Fig. 1). In
sulin stimulates the ovarian production of androgen by activating its homologous receptor,20,21
and the ovaries of women with the polycystic
ovary syndrome appear to remain sensitive to in
sulin,22 or perhaps hypersensitive to it,23-25 even
when classic target tissues such as muscle and
fat manifest resistance to insulin action. In addition, hyperinsulinemia inhibits the hepatic production of sex hormone–binding globulin,26 further increasing circulating free testosterone levels.
Finally, insulin impedes ovulation, either by directly affecting follicular development or by indirectly increasing intraovarian androgen levels
or altering gonadotropin secretion.27 Further evidence of the influence of insulin resistance in
the polycystic ovary syndrome is that multiple
diverse interventions, which are related to one
another only in that they lower circulating insulin levels, result in increased frequency of ovulation or menses, reduced serum testosterone levels, or both. These interventions include the
inhibition of insulin release (with the use of diazoxide20 or octreotide28), improvement of insulin sensitivity (with the use of diet-induced weight
48

n engl j med 358;1

of

m e dic i n e

loss,29 metformin,30,31 troglitazone,32 rosiglita
zone,23,33 or pioglitazone34), or the reduction of
carbohydrate absorption (with the use of acarbose35).
Metformin, a biguanide, is the most widely
used drug for the treatment of type 2 diabetes
worldwide. Its primary action is to inhibit hepatic glucose production, but it also increases
the sensitivity of peripheral tissues to insulin.36
The increase in insulin sensitivity, which contributes to the efficacy of metformin in the treatment of diabetes, has also been shown in nondiabetic women with the polycystic ovary syndrome.37
In women with the syndrome, long-term treatment with metformin may increase ovulation,
improve menstrual cyclicity, and reduce serum
androgen levels30,31; the use of metformin may
also improve hirsutism.38 If published data on
the effects of metformin in the prevention of diabetes can be extrapolated to women with the
polycystic ovary syndrome, then the drug may
actually retard progression to glucose intolerance
in affected women, as reported in a small, retrospective study.39

Cl inic a l E v idence
In 1996, it was reported that the administration
of metformin to women with the polycystic ovary
syndrome reduced circulating insulin levels and
was associated with decreases in ovarian 17,20lyase activity and ovarian secretion of androgens.40 Most, but not all, subsequent studies confirmed the ability of metformin to lower fasting
serum insulin30 and androgen31 levels in women
with the polycystic ovary syndrome. However,
studies specifically assessing the effects of metformin on clinical signs of androgen excess (e.g.,
hirsutism, acne, and androgenetic alopecia) are
limited.38
With regard to ovulation, in results of a randomized clinical trial reported in 1998, pretreatment with metformin, as compared with placebo,
increased the incidence of ovulation after subsequent treatment with clomiphene.41 Subsequently, several studies compared metformin with placebo, metformin with no treatment, metformin
plus clomiphene with clomiphene alone, or metformin plus clomiphene with placebo. The most
rigorous of these studies were included in a
meta-analysis by Lord et al. in 2003.30 The metaanalysis included data from 13 trials and 543

www.nejm.org

january 3, 2008

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 12, 2015. For personal use only. No other uses without permission.
Copyright © 2008 Massachusetts Medical Society. All rights reserved.

Clinical Ther apeutics

Pancreas

Increased
insulin release

Insulin

Genetic
factors

Insulin
resistance

Skeletal
muscle

Pituitary gland

Hyperglycemia
Decreased FSH

Increased LH

Liver

Increased
free fatty acids,
cytokines, PAI-1

Polycystic
ovary

Release of free
fatty acids

Increased
adipose tissue
Increased
androgens

Decreased sex
hormone-binding globulin
production

Figure 1. Pathophysiological Characteristics of the Polycystic Ovary Syndrome (PCOS).
Insulin resistance results in a compensatory hyperinsulinemia, which stimulates ovarian androgen production in an
ovary genetically predisposed to PCOS. Arrest of follicular development (red “X”) and anovulation could be caused
by the abnormal secretion of gonadotropins such as follicle-stimulating hormone (FSH) or luteinizing hormone (LH)
(perhaps induced by hyperinsulinemia), intraovarian androgen excess, direct effects of insulin, or a combination of
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(26.8% and 22.5%, respectively; P = 0.31). In that
study, clomiphene was more effective than metformin in inducing ovulation in the short term
and producing a live birth.
With regard to diabetes, two major randomized clinical trials, the Indian Diabetes Prevention Programme (IDPP-1)45 and the U.S. Diabetes Prevention Program (DPP),46 have shown that
the use of metformin decreases the relative risk
for progression to type 2 diabetes (by 26% and
31%, respectively) among patients with impaired
glucose tolerance at baseline. Whether this effect
of metformin truly represented the prevention of
progression to diabetes, rather than simply the
masking of progression by means of lowering
blood glucose levels, remains controversial. However, after the discontinuation of metformin in
the DPP, diabetes developed in fewer subjects
than would have been expected if masking had
been the sole effect.47 To my knowledge, no randomized clinical trial has assessed the effect of
metformin on the progression to type 2 diabetes
specifically in patients with the polycystic ovary
syndrome. In an uncontrolled, retrospective study
of 50 women with the polycystic ovary syndrome
treated with metformin for an average of 43
months at an academic medical center, there was
no progression to type 2 diabetes, even though
11 women (22.0%) had impaired glucose tolerance at baseline.39 The annual conversion rate
from normal glucose tolerance to impaired glucose tolerance was only 1.4%, as compared with
16 to 19% reported in the literature4,6 for women
with the polycystic ovary syndrome who are not
taking metformin.

Cl inic a l Use
The approach to the management of the polycystic
ovary syndrome depends in part on the patient’s
and physician’s principal therapeutic objectives.
For some women, infertility is the principal issue.
Such patients are frequently treated in the short
term with clomiphene, to induce ovulation. When
fertility is not a concern, an estrogen–progestin
contraceptive, with or without an antiandrogen
such as spironolactone, has been the mainstay of
long-term therapy. This approach is effective in
achieving the traditional treatment goals in the
polycystic ovary syndrome, which include ameliorating the effects of androgen excess (e.g., hir-
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sutism, male pattern baldness, and acne) and
restoring regular menses, thereby preventing endo
metrial hyperplasia.
However, given the metabolic derangements
associated with the polycystic ovary syndrome, it
seems prudent and appropriate to plan long-term
therapy that addresses not only management of
the consequences of androgen excess and anovulation but also the new goals of ameliorating insulin resistance and reducing the risks of type 2
diabetes and cardiovascular disease. The effect of
estrogen–progestin contraceptive agents on glucose tolerance is controversial. Limited evidence
from controlled, short-term studies suggests that
the use of oral contraceptives aggravates insulin
resistance and worsens glucose tolerance in women with the polycystic ovary syndrome.48 The use
of estrogen–progestin contraceptives is associat
ed with a twofold increase in the relative risk of
cardiovascular arterial events in the general female population49; the risk among women with
the polycystic ovary syndrome in particular is
unknown.
Metformin improves insulin sensitivity and,
as noted earlier, has been shown to retard or
prevent progression to type 2 diabetes in patients
with impaired glucose tolerance. Although metformin has not been specifically shown to reduce
the risk of cardiovascular events in patients with
the polycystic ovary syndrome, the available mech
anistic and clinical evidence support the use of
metformin as a protective measure against the
adverse cardiovascular effects of insulin resistance and insulin excess. In addition, metformin
may decrease circulating androgen levels and may
improve ovulation and menstrual cyclicity, thus
addressing the traditional goals of long-term
treatment. For these reasons, although metformin is not approved by the Food and Drug Administration for the treatment of the polycystic
ovary syndrome, the drug is commonly used for
this purpose.
To minimize side effects, metformin therapy
is initiated at a low dose taken with meals, and
the dose is then progressively increased. My practice is to have patients take 500 mg of metformin
once daily with the largest meal, usually dinner,
for 1 week; then increase the dose to 500 mg
twice daily, with breakfast and dinner, for 1 week;
increase the dose to 500 mg with breakfast and
1000 mg with dinner, for 1 week; and finally,
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increase the dose to 1000 mg twice daily, with
breakfast and dinner. There is no dose-ranging
study of metformin in the polycystic ovary syndrome, but a dose-ranging study of patients with
diabetes, using the glycated hemoglobin level as
the outcome measure, suggested that a dose of
2000 mg daily is optimal.50
Metformin should not be used in women
with renal impairment (a serum creatinine level
>1.4 mg per deciliter [124 μmol per liter]), hepatic dysfunction, severe congestive heart failure,
or a history of alcohol abuse. Given the young
age of women with the polycystic ovary syndrome, these contraindications are rarely an issue.
Repeat testing during metformin treatment is not
indicated unless an illness or condition (e.g., dehydration) that might affect renal or hepatic function develops.
When metformin is prescribed, advice about a
weight-loss diet and a scheduled exercise routine
should also be given. Such interventions are
beneficial in preventing diabetes.45,46 In addition,
weight loss increases the likelihood of resuming
ovulation, most likely as a result of improved
insulin sensitivity.29,51
The patient is asked to maintain a menstrual
diary, cautioned that fertility may be rapidly established, and advised to use a barrier method
of contraception. Oral contraceptive agents and
antiandrogens are not administered at the initial
visit, since they might affect menstruation or
serum androgen levels and confound the assessment of the efficacy of metformin. Topical eflor
nithine can be prescribed for the treatment of
facial hirsutism.
Follow-up visits are scheduled at 3 and
6 months. Menstrual cyclicity is reviewed and
serum total testosterone is determined at each
visit. If an improvement in menstrual cyclicity is
noted, it is important to document whether the
menses are ovulatory. This can be accomplished
by measuring the serum progesterone level 7 days
before the next onset of menses; a serum progesterone level of more than 4.0 ng per milliliter
(12.7 nmol per liter) is consistent with the presence of the luteal phase and ovulation.
After 6 to 9 months of treatment, the efficacy
of metformin is assessed. If menstrual cyclicity
and ovulation are satisfactorily improved, further
treatment is individualized. For some women,
treatment with metformin alone might suffice.

n engl j med 358;1

Women desiring contraception could be given an
oral contraceptive agent while continuing to take
metformin. In cases in which hirsutism remains
troublesome, an oral contraceptive agent, antiandrogen, or both could be added to metformin.

A dv er se Effec t s
Lactic acidosis has been reported with the use of
metformin, but this complication is rare (0.3 episode per 10,000 patient-years) in otherwise healthy
patients and is confined primarily to patients who
should not have received the drug, because they had
underlying renal or hepatic disease.
The main limiting side effect of metformin,
affecting 10 to 25% of patients, is gastrointestinal distress, namely nausea and diarrhea. If the
nausea or diarrhea occurs at a given dose, that
dose is either maintained or decreased by 500 mg
per day for 2 to 4 weeks until the symptoms
abate. Fortunately, the gastrointestinal side effects of metformin are usually transient; however,
in a minority of cases, gastrointestinal distress
may require the discontinuation of metformin.
Metformin can cause malabsorption of vitamin
B12 in some patients receiving long-term therapy.
In one analysis, risk factors for the development
of this adverse effect included both the daily dose
and duration of metformin therapy as well as
age.52 Although the likelihood of clinical deficiency of vitamin B12 appears to be low, patients
should be monitored for signs and symptoms.
Metformin is a category B drug, and no teratogenic effects have been found in animal models. It was administered in South Africa to a
limited number of women with type 2 diabetes
or gestational diabetes, throughout their pregnancies, and no teratogenic effects or adverse
fetal outcomes were reported.31

A r e a s of Uncer ta in t y
Although metformin is increasingly used to treat
patients with the polycystic ovary syndrome, therapy is guided in part by the results of randomized, controlled trials in populations without the
polycystic ovary syndrome, which showed that
diabetes was prevented. Similar randomized, controlled trials specifically involving patients with
the polycystic ovary syndrome are needed. Strategies for long-term metformin therapy in patients
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with the polycystic ovary syndrome are evolving,
and the identification of predictors of the response to metformin, possibly even through pharmacogenomic approaches, would improve the
utility of this agent in the management of the
polycystic ovary syndrome. Although long-term
treatment with metformin seems likely to be beneficial in many patients with the polycystic ovary
syndrome, less clear is when metformin should be
used as monotherapy or in combination with anti
androgens or hormonal therapies. The efficacy of
metformin in ameliorating the signs of androgen
excess, such as hirsutism, has not been critically
assessed.
Metformin has been used for many years in
patients with type 2 diabetes. However, we do
not have data regarding the potential long-term
effects of the drug in patients treated for the
polycystic ovary syndrome, in whom therapy, if
effective, may be continued for many years. If a
woman were to become pregnant, it is unclear
whether metformin should be continued during
pregnancy and, if so, for how long.

Guidel ine s
The recent position statement of the Androgen
Excess Society53 recommends that women with
the polycystic ovary syndrome, regardless of
weight, be screened for glucose intolerance with
the use of a glucose-tolerance test at the initial
presentation and every 2 years thereafter. It notes
that the use of metformin to treat or prevent
progression to impaired glucose tolerance may
be considered but should not be mandated until
there have been well-designed randomized, controlled trials demonstrating efficacy. A position
statement of the American Association of Clinical Endocrinologists54 recommends that metformin be considered the initial intervention
in most women with the polycystic ovary syndrome, particularly those who are overweight or
obese.
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R ec om mendat ions
The obesity, family history of diabetes, and polycystic ovary syndrome of the patient in the vignette
put her at high risk for type 2 diabetes. In addition to obesity, she has several signs of insulin
resistance, including a low serum high-density
lipoprotein cholesterol level and a high triglyceride level, and her data fulfill the Adult Treatment
Panel III criteria of the National Cholesterol Education Program for the metabolic syndrome.55,56
Although her glucose tolerance is currently normal, treatment with metformin is reasonable,
and a weight-loss diet and exercise are also encouraged.
Although fertility is not an immediate concern, it is likely that metformin will increase the
frequency of ovulation, thereby improving menstrual cyclicity. Once menstrual cyclicity has improved, I would determine whether ovulation is
occurring by measuring the serum progesterone
level during the presumed luteal phase. Since the
patient does not tolerate oral contraceptives, a
barrier method of contraception could be recommended. When and if the patient desires pregnancy, fertility may be improved if the frequency
of ovulation increases during metformin therapy.
If not, the patient should be evaluated for causes
of infertility unrelated to anovulation, and the
addition of clomiphene to her regimen should be
discussed.
I would see the patient every 3 months during
the first year, not only to monitor the efficacy of
metformin but also to reinforce lifestyle changes
to reduce weight and increase physical activity.
Thereafter, she could be seen every 6 to 12 months,
depending on the response to treatment. Given
that she is at high risk for diabetes, I would repeat
the oral glucose-tolerance test every 2 to 3 years,
even if metformin therapy is used.
Supported by grants from the National Institutes of Health
(R01HD035629, K24D040237, and D43TW007692).
No potential conflict of interest relevant to this article was
reported.
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